Evidence mapPaperPMID 39201668Full record

ReviewInternational journal of molecular sciences2024

Carotenoid Supplementation for Alleviating the Symptoms of Alzheimer's Disease.

Jolanta Flieger, Alicja Forma, Wojciech Flieger, Michał Flieger, Piotr J Gawlik, Eliasz Dzierżyński, Ryszard Maciejewski, Grzegorz Teresiński, Jacek Baj

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Neuroprotective Potential ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jolanta FliegerDepartment of Analytical Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland.ORCID 0000-0001-6881-3161
Alicja FormaDepartment of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland.ORCID 0000-0001-8714-7627
Wojciech FliegerDepartment of Plastic Surgery, St. John's Cancer Center, ul. Jaczewskiego 7, 20-090 Lublin, Poland.ORCID 0000-0002-0509-868X
Michał FliegerDepartment of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland.
Piotr J GawlikDepartment of Plastic Surgery, St. John's Cancer Center, ul. Jaczewskiego 7, 20-090 Lublin, Poland.
Eliasz DzierżyńskiDepartment of Plastic Surgery, St. John's Cancer Center, ul. Jaczewskiego 7, 20-090 Lublin, Poland.
Ryszard MaciejewskiInstitute of Health Sciences, John Paul II Catholic University of Lublin, Konstantynów 1 H, 20-708 Lublin, Poland.
Grzegorz TeresińskiDepartment of Forensic Medicine, Medical University of Lublin, ul. Jaczewskiego 8b, 20-090 Lublin, Poland.ORCID 0000-0002-4184-9305
Jacek BajDepartment of Correct, Clinical and Imaging Anatomy, Medical University of Lublin, ul. Jaczewskiego 4, 20-090 Lublin, Poland.ORCID 0000-0002-1372-8987

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is characterized by, among other things, dementia and a decline in cognitive performance. In AD, dementia has neurodegenerative features and starts with mild cognitive impairment (MCI). Research indicates that apoptosis and neuronal loss occur in AD, in which oxidative stress plays an important role. Therefore, reducing oxidative stress with antioxidants is a natural strategy to prevent and slow down the progression of AD. Carotenoids are natural pigments commonly found in fruits and vegetables. They include lipophilic carotenes, such as lycopene, α- and β-carotenes, and more polar xanthophylls, for example, lutein, zeaxanthin, canthaxanthin, and β-cryptoxanthin. Carotenoids can cross the blood-brain barrier (BBB) and scavenge free radicals, especially singlet oxygen, which helps prevent the peroxidation of lipids abundant in the brain. As a result, carotenoids have neuroprotective potential. Numerous in vivo and in vitro studies, as well as randomized controlled trials, have mostly confirmed that carotenoids can help prevent neurodegeneration and alleviate cognitive impairment in AD. While carotenoids have not been officially approved as an AD therapy, they are indicated in the diet recommended for AD, including the consumption of products rich in carotenoids. This review summarizes the latest research findings supporting the potential use of carotenoids in preventing and alleviating AD symptoms. A literature review suggests that a diet rich in carotenoids should be promoted to avoid cognitive decline in AD. One of the goals of the food industry should be to encourage the enrichment of food products with functional substances, such as carotenoids, which may reduce the risk of neurodegenerative diseases.

Indexed as

Alzheimer DiseaseCarotenoidsDietary SupplementsAnimalsAntioxidantsCognitive DysfunctionHumansNeuroprotective AgentsOxidative StressAntioxidantsCarotenoidsNeuroprotective AgentsAlzheimer’s diseasebraincarotenoidscognitive dysfunctiondementiamemory lossnatural productsneuroprotection

Identifiers

PMID39201668
PMCPMC11354426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.